Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

Salesforce (NYSE: CRM), the world's #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliver life-changing medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.

With Agentforce Life Sciences, Salesforce aims to help AstraZeneca unlock a new era of intelligent engagement — redefining customer relationships and accelerating business growth. The partnership will enable teams to focus on strategic customer outcomes and meaningful customer interactions.

Expanding its remit for AstraZeneca, Salesforce will support Agentforce 360 for Life Sciences as the global, end-to-end engagement solution for AstraZeneca, including:

  • Medical-Commercial Coordination: Consolidating healthcare professional (HCP) insights and surface context across teams.
  • Personalized Engagement: Scaling operations across key account, reimbursement, and field teams with next-best action recommendations. AstraZeneca will also orchestrate and automate digital campaigns across multiple channels based on customer preferences.
  • Model Context Protocol (MCP) Interoperability: Extending its composable architecture with Salesforce's Agent Fabric , AstraZeneca will orchestrate internal and external agent actions across field engagement, commercial operations, and different brands and regions, allowing its care teams and AI agents to work seamlessly together.

"This partnership with AstraZeneca represents a clear step towards building intelligent, agentic customer engagement in the life sciences industry with their selection of Agentforce Life Sciences for Customer Engagement," said Frank Defesche, SVP and GM of Life Sciences at Salesforce. "Together, we will empower AstraZeneca's teams with the latest technology to deliver personalized engagement and accelerate the delivery of life-changing medicines to patients around the world."

Learn more:

About Salesforce

Salesforce helps organizations of any size become Agentic Enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information.

Any unreleased services or features referenced here are not currently available and may not be delivered on time or at all. Customers should make their purchase decisions based upon features that are currently available.

Maha Neouchy
Salesforce
Public Relations
408-568-8442
pr@salesforce.com

News Provided by Business Wire via QuoteMedia

CRM
The Conversation (0)
Nine Mile Metals Announces Phase 1 Bulk Sample Update at Nine Mile Brook High Grade Lens of 13.71% CuEq over 15.10m

Nine Mile Metals Announces Phase 1 Bulk Sample Update at Nine Mile Brook High Grade Lens of 13.71% CuEq over 15.10m

Nine Mile Metals LTD. (CSE: NINE,OTC:VMSXF) (OTC Pink: VMSXF) (FSE: KQ9) (the "Company" or "Nine Mile") is pleased to announce that it is conducting Bulk Sample Metallurgical Analysis on the Nine Mile Brook VMS High Grade Lens with SGS Canada and Glencore Canada. Glencore and SGS will be... Keep Reading...
Allied Critical Metals Delivers Robust Initial PEA at the Borralha Project

Allied Critical Metals Delivers Robust Initial PEA at the Borralha Project

After-Tax NPV(8%) of $473M and IRR of 49% at USD $1,000/mtu WO3; Fully funded 20,000m Drill Program Underway to Expand Scale of the Borralha Project Key Highlights: Robust Economics: After-tax NPV(8%)1 of $473.4 million (USD $346.6 million) and IRR2 of 48.8% at USD $1,000/mtu WO₃3. Capital... Keep Reading...
New Age Metals Reports Up To 51.9% Antimony And 46.2 G/T Gold From Phase 2 Exploration At St. Alban's, Newfoundland

New Age Metals Reports Up To 51.9% Antimony And 46.2 G/T Gold From Phase 2 Exploration At St. Alban's, Newfoundland

(TheNewswire) February 27, 2026 TheNewswire - Rockport, Ontario– New Age Metals Inc. (TSX.V: NAM | OTCQB: NMTLF | FSE: P7J) ("NAM" or the "Company") is pleased to report results from its Phase 2 follow-up exploration program at the Company's St. Alban's antimony–gold properties in southern... Keep Reading...
New Found Gold Announces Preliminary Economic Assessment and Updated Mineral Resource Estimate for the Hammerdown Gold Project

New Found Gold Announces Preliminary Economic Assessment and Updated Mineral Resource Estimate for the Hammerdown Gold Project

Hub and Spoke Mine Plan in Central Newfoundland: Three deposits, Hammerdown, Orion and Stog'er Tight, centered around the Company's Pine Cove Mill Robust Economics: After-tax NPV5%[1] of $199.2 M[2] using a base case scenario (variable price deck: long-term price of US$3,475/oz averaging... Keep Reading...
Tartisan Nickel Corp. Intersects 3.0 Metres of 2.17% Ni, 1.45% Cu at The Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

Tartisan Nickel Corp. Intersects 3.0 Metres of 2.17% Ni, 1.45% Cu at The Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

Tartisan Nickel Corp. (CSE: TN,OTC:TTSRF) (OTCQX: TTSRF) (FSE: 8TA) ("Tartisan", or the "Company") is pleased to provide an update of the Company's flagship Kenbridge Nickel-Coppet-Cobalt Project. The drill program is designed to test the on strike and down dip potential for additional nickel... Keep Reading...

Interactive Chart

Latest Press Releases

Related News